


Thursday March 11 th , 2010	Lecture Hall VI 02:00 pm - 04:30 pm	Session 35 Symposium	
---	--	-------------------------	---

The Problem of Antibiotic Resistance, Superbugs and the Need for New Drugs - Part A

Moderators: Alan S. Cross, Baltimore, USA
Steven M. Opal, Pawtucket, USA


- 02:00 - 02:20 **SY 307** Bacterial Pathogens in the Clinic and Community: The Need for New Antibiotics
Steven M. Opal, Pawtucket, USA
- 02:20 - 02:40 **SY 308** Antibiotic Resistance: Where does it Come From and What Can we do About It?
Philippe Moreillon, Lausanne, Switzerland
- 02:40 - 03:00 **SY 309** Where Will New Antibiotics Come from?
Patricia A. Bradford, Cambridge, USA
- 03:00 - 03:20 **SY 310** An Approach to New Antibiotics for Avoiding Resistance: PMX-30063 (A 418)
Eric McAllister, Radnor, USA
- 03:20 - 03:40 **SY 311** New Antibiotic Targets - Virulence and Quorum Sensing (A 402)
Evangelos J. Giamarellos-Bourboulis, Athens, Greece
- 03:40 - 04:00 **SY 311a** What Makes a 'Good' Antibiotic? The Intensivist's Perspective
Philip S. Barie, New York City, USA
- 04:00 - 04:20 **SY 312** Novel Antibiotics under Development
Joseph S. Solomkin, Cincinnati, USA



Under the Auspices of the Paul-Ehrlich-Gesellschaft (PEG)



*Supported with an Unrestricted Educational Grant of
NOVARTIS INTERNATIONAL AG*

Thursday March 11 th , 2010	Lecture Hall VI 04:30 pm - 06:45 pm	Session 36 Symposium	
---	--	-------------------------	---

The Problem of Antibiotic Resistance, Superbugs and the Need for New Drugs - Part B

Moderators: Steven M. Opal, Pawtucket, USA
Joseph S. Solomkin, Cincinnati, USA

- | | | |
|---------------|----------------|---|
| 04:30 - 04:50 | SY 312a | Hybrid Antibiotics: Dual Mode of Action for the Treatment of Nosocomial Infections with Multi-Resistant Germs
Guenther Ross, Munich, Germany |
| 04:50 - 05:10 | SY 313 | A New Generation of Beta-Lactamase Inhibitors (A 408)
Carol A. Sable, Philadelphia, USA |
| 05:10 - 05:30 | SY 314 | Pharmacokinetic Approaches to Optimize Antibiotic Effectiveness
Johan Mouton, Nijmegen, Netherlands |
| 05:30 - 05:50 | SY 315 | Kill the Bacteria... and also their Messengers? (A 221)
Robert S. Munford, Bethesda, USA |
| 05:50 - 06:10 | SY 316 | Bacteriophages as an Antibacterial Strategy (A 413)
David R. Harper, Nottingham, United Kingdom |
| 06:10 - 06:30 | SY 317 | What about the Host (Microbiome, Modulation of Host Immunity as an Antiinfective Strategy)?
John C. Alverdy, Chicago, USA |



Under the Auspices of the Paul-Ehrlich-Gesellschaft (PEG)



*Supported with an Unrestricted Educational Grant of
NOVARTIS INTERNATIONAL AG*